There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Shares in Gilead have been under pressure in recent months but gained a couple of points after the announcement. Analysts at Jefferies said that after a period of mixed success in R&D for Gilead ...

He sees only a 25% chance of success however, and a miss would make it harder for Gilead chief executive Daniel O'Day to meet his target of making one third of revenues from cancer drugs in 2030.

In this article, we are going to take a look at where Gilead Sciences ... On the flip side, the success of GLP-1 receptor agonists is sparking renewed interest in general medicines, with companies ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ ... in late-stage trials following recent setbacks. The success of long-term PrEP may further complicate vaccine ...